Physicians need to be more upfront with their patients about the benefits and harms of the medications we prescribe.
On RemeGen (688331.SH/09995.HK) announced that the results of the Phase III clinical study of Telitacicept for Sjögren's Syndrome in China have been published in an abstract on the 2025 ACR website.
PRESS RELEASE AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF ...
Gozellix is now a fully reimbursed product in the U.S., having been granted a Level II HCPCS code 14 and TPT payment status (effective 1 October 2025) 15. Telix is the only company with two U.S. Food ...
An Estimated 1 Million Cats Prowl the Streets of Cyprus as Officials Scramble to Check Their Numbers
The island of cats has a cat problem. Officials in Cyprus, the small island nation in the eastern corner of the Mediterranean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback